Role of a novel transcriptional repressor gene, ZFP-BA, in colon cancer proliferation and apoptosis

• Project/Area Number: 23590952
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Aichi Medical University
• Principal Investigator: OGASAWARA NAOTAKA 愛知医科大学, 医学部, 准教授 (00433219)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 大腸癌 / 上皮細胞増殖因子 / アンギオテンシンII受容体拮抗薬 / 遺伝子

Research Abstract

ZFP-BA, a novel transcriptional repressor gene, degradation caused by interaction with the Heparin-binding epidermal growth factor-like growth factor-C-terminal fragment (HB-EGF-CTF) should induce some important factors for cell proliferation and inhibit others for cell apoptosis in colon cancers. The inhibition of interactions between HB-EGF-CTF and ZFP-BA is considered essential because agents that can inhibit HB-EGF-CTF translocation might suppress ZFP-BA downregulation.
Telmisartan, angiotensin II type 1 receptor blockers (ARBs), is one of the candidate inhibitors of HB-EGF-CTF nuclear translocation in vitro. However, treatment for humans with colon cancer would require high volume of telmisartan to prevent cell proliferation. The inhibition of HB-EGF-CTF nuclear translocation signaling will comprise a new strategy against the development of colorectal cancer. ZFP-BA might become one of the targets of future strategies to treat colon cancers.